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Two recent papers inCancer Cell (Lu et al., this issue ofCancer Cell, and Kang et al.) illustratemeanswhereby
acquisition of VCAM-1 by tumor cells can promote metastasis. First, monocyte/macrophages expressing a4
integrin bind VCAM-1 and provide survival signals enhancing establishment of metastases. Second, VCAM-1
allows dormant tumor cells to interact with osteoclasts, yielding paracrine signals and enhancing osteolytic
metastatic growth.Cancer is a leading cause of death, and
most patients die from metastases rather
than from primary tumors. Therefore,
metastasis is subject to intense research
investigations seeking to understand this
interesting biological process and to
provide better means of treatment. Much
has been learned about the changes
giving rise to primary tumors, and novel
targeted therapies are based on that
knowledge. However, it is clear that tumor
cells have often already left the primary
tumor site and dispersed throughout the
body when primary tumors are diag-
nosed. Circulating tumor cells (CTCs) are
found in the blood, and disseminated
tumor cells (DTCs) can be found in
ectopic sites such as lymph nodes and
bone marrow, where they can persist for
years and only later develop into clinically
relevant metastases. The incidences of
both types are indicators of poor prog-
nosis for cancer progression.
The probability for both CTCs and
DTCs to become clinically relevant
metastases is low; most CTCs fail to
seed productively in a distant site, and
many DTCs remain dormant for years.
Arrest and establishment of a potentially
metastatic cell at a secondary site
requires several steps: (1) survival in the
circulation, (2) initial arrest, (3) extravasa-
tion, (4) initial seeding and establishment
of a supportive niche allowing survival of
the displaced cancer cells, (5) eventual
growth into a colony or micrometastasis,
and (6) subsequent growth into a sec-
ondary tumor/macrometastasis. While
only the last presents an actual clinical
problem, the earlier steps are essential
and, based on results of various analyses,
frequently fail. Tumor dormancy, which
can last a long time, intervenes at steps
5 and 6. The challenges are to deducewhat mechanisms allow some CTCs to
home and seed effectively at distant sites
and establish a proliferating secondary
tumor and what changes allow dormant
DTCs to resume growth.
Two recent papers in Cancer Cell
provide new information bearing on these
questions. In the first, Chen et al. (2011)
describe investigations of a gene whose
expression they found upregulated in
derivatives of MDA-MB-231, a human
mammary carcinoma line commonly
used in studies of metastasis. It is
possible to introduce such cells into the
circulation and select for variants that
show high propensity for metastasis to
one or another secondary site. In this
case, selection was for metastasis to the
lung, and a variety of variants were
selected and analyzed. These variants
shared a gene expression signature,
lung metastasis signature, differing from
that of the parental MDA-MB-231 line
and from those of variants selected for
metastasis to bone or brain (Minn et al.,
2005). Among the genes in the lung
metastasis signature were several subse-
quently shown to enhance extravasation
of the introduced CTCs in the lung.
Another upregulated gene encodes
VCAM-1, a cell-cell adhesion protein
best known for its involvement in recruit-
ing leukocytes to inflamed endothelium
(which expresses VCAM-1) or to the
bone marrow. Many hematopoietic cells
express a4 integrins, a4b1 or a4b7, which
bind to either VCAM-1 on other cells or
fibronectin in the extracellular matrix.
The a4-integrin-mediated adhesion plays
important roles in recruiting and main-
taining hematopoietic stem and progen-
itor cells and in the homing of lympho-
cytes and myeloid cells to sites of
inflammation.Cancer Cell 20, DThe occurrence of VCAM-1 on meta-
static tumor cells naturally suggested
that it might play some analogous role in
recruitment, arrest, or extravasation of
the tumor cells. However, Chen et al.
(2011) showed that the presence of
VCAM-1 on these cells did not enhance
transendothelial migration and had little
if any effect on the early recruitment of
metastatic cells to the lung. Thus, it
appeared that VCAM-1 interactions were
not important for arrest, extravasation, or
initial seeding (steps 2–4 above).
However, VCAM-1 did enhance longer-
term tumor cell survival and growth of
lung metastases and Chen et al. (2011)
showed that this was because VCAM-1
on the tumor cells binds monocytes
through a4-integrin-mediated adhesion.
Furthermore, this cell-cell adhesion
provides survival signals to the tumor cells
and prevents their apoptosis. This re-
quires clustering of the surface VCAM-1
and recruitment of phosphorylated ezrin
by the cytoplasmic domain of VCAM-1;
ezrin in turn recruits PI3-kinase and acti-
vates Akt, providing the antiapoptotic
signal. Chen et al. (2011) further show
that VCAM-1 levels are elevated in breast
cancer metastases to lung and bone, but
not in those to brain, and that high levels
of VCAM-1 correlate with elevated leuko-
cyte infiltration. This suggested that
leukocytes promote growth and survival
of metastases if the tumor cells express
VCAM-1 and thus select for VCAM-posi-
tive cells. It is somewhat surprising that
overexpression of VCAM-1 did not
enhance metastasis of MDA-MB-231
cells to bone even though bone marrow
is replete with a4-integrin-positive cells,
both hematopoietic cells and others—
presumably, additional factors are
needed for establishment of metastasesecember 13, 2011 ª2011 Elsevier Inc. 689
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Previewsin the bone marrow. The results of
Chen et al. (2011) establish a role for
VCAM-1/a4 integrin interactions in steps
5 and 6: survival and growth of a
macrometastasis.
The second paper, published in this
issue of Cancer Cell, reveals additional
roles for VCAM-1 in emergence from
dormancy of DTCs (Lu et al., 2011). These
researchers were studying clones of
MDA-MB-231 that failed to give rise to
bone metastases for several months after
introduction into mice. However, after
4 months, tumors appeared in various
bones in a small proportion of the injected
mice. Further investigation showed that
some of the initially injected cells had
lodged in the bones but failed to grow
into metastases—that is, they were
dormant. However, with low frequency,
some could emerge from dormancy and
develop into frank metastases. Cells iso-
lated from such metastases were vigor-
ously metastatic to bone when retested.
Comparison of gene expression signature
of these new variants with that of others
originally isolated for their ability to estab-
lish rapid bone metastases showed that
the new DTC-derived cells did not reca-
pitulate the original bone metastasis
signature, which includes a set of genes
that allow the cells to set up a paracrine
signaling network between tumor cells
and bone cells (Kang et al., 2003) and
instead expressed a different set of
genes. Testing some of these genes for690 Cancer Cell 20, December 13, 2011 ª20functional involvement by knockdowns
implicated VCAM-1 and overexpression
of VCAM-1 in appropriate cell lines
produced activelymetastatic cells. Exam-
ination of other lines confirmed the gener-
ally prometastatic role of VCAM-1 and
antibodies against VCAM-1 or a4 integ-
rin-reduced growth of the metastases.
So, how does VCAM-1 confer meta-
static capacity in this case? It turned out
that expression of VCAM-1 increased
the numbers of differentiated osteoclasts
and established a paracrine support
circuit between osteoclasts and the tumor
cells. VCAM-1 contributed to the increase
in osteoclast numbers in two ways:
soluble VCAM-1 released from the tumor
cells acts as a chemoattractant for preos-
teoclasts (which are a4-integrin-positive),
and a4 integrin/VCAM-1-mediated adhe-
sion of preosteoclasts to the tumor cells
enhances their differentiation and estab-
lishes a paracrine cycle between tumor
cells, osteoclasts and osteoblasts that
enhances tumor growth.
So, acquisition of VCAM-1 by poten-
tially metastatic mammary carcinoma
cells can enhance their metastatic
capacity through at least two different
mechanisms: by monocyte/macrophage
lineage cells clustering VCAM-1 on tumor
cells and providing survival signals
or by paracrine interactions between
dormant tumor cells and osteoclasts to
establish a vicious cycle of intercellular
stimulation to enhance osteolytic meta-11 Elsevier Inc.static growth. Since a4 integrins are ex-
pressed by a variety of cells present in
the tumor microenvironment (lympho-
cytes, lymphatics, cells of the blood
vessel wall, as well as myeloid cells), it
seems plausible that additional advan-
tages may accrue to tumor cells that
express VCAM-1, in the form of additional
VCAM-1/ a4 integrin interactions. On the
brighter side, drugs (e.g., nataluzimab)
are already in clinical use to inhibit such
interactions in the context of autoimmune
diseases and, with further research, it may
be possible to deploy them also against
metastasis. Since both examples dis-
cussed in these two papers concern
long-term maintenance of metastases
rather than their initial seeding, it is real-
istic to consider such approaches target-
ing preexisting metastases.REFERENCES
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